ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

SANDOSTATIN LAR DEPOT
Cytoprotective and supportive care agents
Pituitary disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

SANDOSTATIN LAR DEPOT Rx

Generic Name and Formulations:
Octreotide acetate 10mg, 20mg, 30mg; susp for IM inj after dilution; contains mannitol.

Company:
Novartis Pharmaceuticals Corp

Therapeutic Use:

Indications for SANDOSTATIN LAR DEPOT:

Long-term treatment of severe diarrhea and flushing due to metastatic carcinoid tumors; and profuse watery diarrhea due to vasoactive intestinal peptide-secreting tumors in patients whom immediate-release (IR) octreotide acetate has been shown to be effective and tolerated.

Adult:

Give by intragluteal IM inj. Not currently receiving octreotide: initiate therapy with immediate-release octreotide SC inj for at least 2 weeks. Continue immediate-release octreotide therapy for ≥2 weeks, up to 3 or 4 weeks, after initial switch to LAR. Initially 20mg every 4 weeks for 2 months. After 2 months: if symptoms are controlled, may reduce to 10mg every 4 weeks; if symptoms are not controlled, may increase to max 30mg every 4 weeks. Dialysis or cirrhosis: initially 10mg every 4 weeks. Treat exacerbations with immediate-release octreotide SC inj at same dosage prior to switch.

Children:

Not recommended.

Warnings/Precautions:

Diabetes. Hypothyroidism. Cardiovascular disease. Renal or hepatic impairment. Carcinoid tumors: monitor 5-HIAA, plasma serotonin, plasma Substance P. VIPomas: perform baseline and periodic total and/or free T4 measurements with chronic therapy. Monitor thyroid function, gallbladder, glucose, vitamin B12. Pregnancy (Cat.B). Nursing mothers.

Interactions:

Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers). Antagonizes cyclosporine. Not compatible with TPN solutions. May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance.

See Also:

SANDOSTATIN

Pharmacological Class:

Somatostatin analogue.

Adverse Reactions:

Gallbladder abnormalities (eg, gallstones, biliary sludge), GI upset, bradycardia, conduction abnormalities, arrhythmias, hyperglycemia, hypoglycemia, hypothyroidism, injection site pain, headache, dizziness, pancreatitis, altered dietary fat absorption.

How Supplied:

Ampules 50mcg/mL, 100mcg/mL, 500mcg/mL (1mL)—10; LAR kit—1 (5mL vial w. supplies)

Indications for SANDOSTATIN LAR DEPOT:

Long-term maintenance therapy of acromegaly in patients who have had an inadequate response or cannot be treated with surgery and/or radiotherapy and in whom immediate-release (IR) octreotide acetate is effective and tolerated.

Adult:

Give by intragluteal IM inj. Not currently receiving octreotide: initiate therapy with immediate-release octreotide SC inj for at least 2 weeks. Switching from octreotide IR: initially 20mg every 4 weeks for 3months. After 3months, adjust as follows: GH≤2.5ng/mL, IGF-1 normal and clinical symptoms controlled: maintain dosage at 20mg every 4 weeks; GH≤1ng/mL, IGF-1 normal and clinical symptoms controlled: reduce to 10mg every 4 weeks; GH>2.5ng/mL, IGF-1 elevated and/or clinical symptoms uncontrolled: increase to 30mg every 4 weeks; may increase to max 40mg every 4 weeks. Pituitary irradiation recipients: withdraw therapy for 8 weeks once yearly to assess disease activity; resume if GH or IGF-1 levels increase or signs/symptoms recur.

Children:

Not recommended.

Warnings/Precautions:

Diabetes. Hypothyroidism. Cardiovascular disease. Renal or hepatic impairment. Monitor growth hormone, IGF-1 levels, thyroid function, gallbladder, glucose, vitamin B12. Pregnancy (Cat.B). Nursing mothers.

Interactions:

Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers). Antagonizes cyclosporine. Not compatible with TPN solutions. May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance.

See Also:

SANDOSTATIN

Pharmacological Class:

Somatostatin analogue.

Adverse Reactions:

Gallbladder abnormalities (eg, gallstones, biliary sludge), GI upset, bradycardia, conduction abnormalities, arrhythmias, hyperglycemia, hypoglycemia, hypothyroidism, injection site pain, headache, dizziness, pancreatitis, altered dietary fat absorption.

How Supplied:

Ampules 50mcg/mL, 100mcg/mL, 500mcg/mL (1mL)—10; LAR kit—1 (5mL vial w. supplies)

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs